Navigation Links
Takeda Completes Acquisition of Millennium
Date:5/14/2008

OSAKA, Japan, and CAMBRIDGE, Mass., May 14 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda", TSE: 4502) and Millennium Pharmaceuticals, Inc. ("Millennium", Nasdaq: MLNM) today announced the completion of Takeda's acquisition of Millennium for US$25.00 per share in cash. Takeda completed the acquisition through a tender offer and subsequent merger of a wholly-owned subsidiary of Takeda into Millennium. Millennium is now a wholly-owned subsidiary of Takeda.

"The successful completion of this transaction underscores our ongoing commitment to becoming a global leader in oncology by delivering novel therapies that improve the standards of care for patients. Additionally, the Millennium clinical trial programs for irritable bowel disease (IBD) will enhance our GI franchise. We look forward to a successful transition by working closely with the talented Millennium employees now that they are part of Takeda," said Yasuchika Hasegawa, President of Takeda Pharmaceutical Company Limited.

"As part of the Takeda Group, Millennium will continue its commitment to developing breakthrough medicines that will benefit patients around the world. Millennium is excited to serve as Takeda's global center for oncology as we work with our new colleagues at Takeda to drive scientific excellence and create a world-class pipeline and products," said Deborah Dunsire, M.D., President and Chief Executive Officer of Millennium.

As a result of the merger, each outstanding share of Millennium common stock not validly tendered and accepted for payment in the tender offer (other than any shares in respect of which appraisal rights are validly exercised under Delaware law and any shares owned by Millennium, Takeda or any of their subsidiaries) was converted into the right to receive the same US$25.00 cash per share price paid in the tender offer. Effective after the close of market today, trading in Millennium common stock on the Nasdaq Global Select Market wi
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Takeda Commences Cash Tender Offer for all Outstanding Shares of Millennium
2. Takeda, Abbott Announce Plans to Conclude TAP Joint Venture
3. Takeda Announces New U.S. Leadership
4. Takeda submits new drug application for alogliptin (syr-322) in the US
5. Chemizon Announces Research Collaboration Expansion With Takeda
6. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
7. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
8. InfoLogix Completes $25 Million Senior Debt Financing
9. ConforMIS Completes Executive Team With Addition of CFO
10. Facet Solutions, Inc. Completes Combination Facet Joint and Disc Replacement Study
11. Cardiva Medical, Inc. Completes $15.5 Million Private Equity Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... Sharenote, a leading web-base electronic healthcare software ... this week in Louisiana. The entrepreneurial trio behind Sharenote, ... provide potential providers with the tools and resources to ... within their network. , Find out why Sharenote ... by more than 250 practices. , Four Day ...
(Date:6/1/2015)... June 01, 2015 KC and Monica ... $88,000 of the best superfood products in ... floods in Texas. , "Monica and I are ... News in distributing Living Fuel Super Meals - SuperBerry®, ... millennial floods in Texas," KC Craichy said. "We have ...
(Date:6/1/2015)... 2015 More than 22 million children may ... school is out and they lose access to free or ... dairy farmers and milk companies are on a mission to ... Great American Milk Drive. , In many cases, food ... school cafeteria for the bulk of their daily nutrition. Although ...
(Date:6/1/2015)... CA (PRWEB) June 01, 2015 ... Assili are now offering patients a promotion on Invisalign ... price of Invisalign treatment is reduced to $3,700. Patients ... during the complimentary consultation and discuss the extent of ... and it cannot be combined with any other offer. ...
(Date:6/1/2015)... Listen to Volvo’s Director of Connectivity ... using more granular data to create better customer oriented ... voices in Josep Celaya Gonzalez, CIO at MAPFRE, and ... an automotive insurer, MAPFRE are well versed in capturing ... to the driver. Award winning start-up ParkTAG offer an ...
Breaking Medicine News(10 mins):Health News:Nearly $100,000 In Emergency Food Aid to Flood Victims in Texas Provided by Living Fuel and Natural News 2Health News:Nearly $100,000 In Emergency Food Aid to Flood Victims in Texas Provided by Living Fuel and Natural News 3Health News:Summer Nutrition Vital for Kids who Depend on Schools for Healthy Foods 2Health News:Northridge Dentists, Drs. Michel Elyson and Ramin Assili, are Now Offering a Limited Time Promotion on Invisalign 2Health News:Complimentary Webinar: Volvo, MAPFRE and Award Winning Start-Up discuss new Frontier of In-Car Services 2
... consumption, study finds , , THURSDAY, Nov. 27 (HealthDay News) ... other sugar-sweetened drinks from school cafeteria menus will have ... , Because these drinks are believed to be ... in the United States, many schools across the nation ...
... Montreal, Canada, November 27, 2008 Suffering from ... at the Centre hospitalier de l,Universit de Montral (CHUM), ... high efficacy hemodiafiltration (HDF). , An extracorporeal blood ... the HDF unit was introduced in CHUM,s Nephrology section, ...
... inhibits bacterial growth, experts say , , THURSDAY, Nov. ... cranberry sauce on your plate this Thanksgiving, because it may ... the American Urological Association. , The high acid content ... remedy for simple UTIs, help inhibit bacterial growth along the ...
... 27 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc.,(NYSE: ... medical device,research and development outsourcing company with operations ... Hu, the Company,s Chief Operating,Officer, will present at ... December 3, 2008, at 12:00 pm Eastern Standard ...
... auction special Pinot Noirs to benefit healthcare services for seasonal vineyard ... for 17 years, producers preview outstanding 2007 vintage. , ... ... Salud! The Oregon Pinot Noir Auction contributed generously to the 17th ...
... patients will benefit, researchers say , , WEDNESDAY, Nov. 26 (HealthDay ... with a certain type of non-Hodgkin lymphoma have a better ... , Three different signatures of gene activity, or ... gene -- have been identified in people with diffuse large ...
Cached Medicine News:Health News:School Soda Ban Has Limited Effect 2Health News:Major North American breakthrough for dialysis patients 2Health News:Major North American breakthrough for dialysis patients 3Health News:Cranberries May Help Prevent Urinary Tract Infections 2Health News:WuXi PharmaTech to Present at 20th Annual Piper Jaffray Healthcare Conference 2Health News:Despite Economy, Oregon Wine Benefit !Salud! Raises Over $735,000 2Health News:Despite Economy, Oregon Wine Benefit !Salud! Raises Over $735,000 3Health News:Genes May Predict Lymphoma Treatment Outcome 2
(Date:6/1/2015)... MENLO PARK, Calif. , June ... (OTCQX: DMPI) ("DelMar" and the "Company"), a ... cancer therapies in new orphan drug indications, today ... clinical trial of  VAL-083  (dianhydrogalactitol) in patients with ... deadly form of human brain cancer. ...
(Date:6/1/2015)... SAN DIEGO , June 1, 2015  Diomics, ... Richard M. Weissman , global financial executive, has ... Mr. Weissman has more than 25 years of industry ... Diomics, he served as a managing director at Credit ... UBS and Morgan Stanley/Dean Witter. "Diomics is ...
(Date:6/1/2015)... 1, 2015  AbbVie (NYSE: ABBV ) will ... June 4, 2015. Richard A. Gonzalez , chairman ... and answer session at 8:30 a.m. Central time. ... be accessible through AbbVie,s Investor Relations Web site at ... will be available later that day. ...
Breaking Medicine Technology:DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 2DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 3DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 4DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 5DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 6DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 7DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 8Richard M. Weissman joins Diomics Board of Directors 2
... SuccessEHS, a nationally recognized, streamlined practice management and ... ambulatory care software solution with a signature Success Architecture ... With this pairing, SuccessEHS is well-positioned to meet ... The essential technical, functional and reporting needs of a ...
... 21, 2011 Sheffield Bio-Science, a Kerry Group Business, ... alliance with Wockhardt Ltd. Under this partnership, Sheffield Bio-Science ... for recombinant insulin manufactured by global Indian biotech Wockhardt. ... is around US$ 50 million. Speaking on ...
Cached Medicine Technology:SuccessEHS Announces its Enterprise Ambulatory EHR Solution for Hospitals 2SuccessEHS Announces its Enterprise Ambulatory EHR Solution for Hospitals 3SuccessEHS Announces its Enterprise Ambulatory EHR Solution for Hospitals 4Sheffield Bio-Science and Wockhardt Announce Worldwide Exclusive Partnership to Supply Recombinant Insulin to Cell Culture Market 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: